Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

Anne-Marie C. Dingemans, Ross A. Soo, Abdul Rahman Jazieh, Shawn J. Rice, Young Tae Kim, Lynette L. S. Teo, Graham W. Warren, Shu-Yuan Xiao, Egbert F. Smit, Joachim G. Aerts, Soon Ho Yoon, Giulia Veronesi, Francesco De Cobelli, Suresh S. Ramalingam, Marina C. Garassino, Murry W. Wynes, Madhusmita Behera, John Haanen, Shun Lu, Solange PetersMyung-Ju Ahn, Giorgio V. Scagliotti, Alex A. Adjei, Chandra P. Belani*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review


The global coronavirus disease 2019 pandemic continues to escalate at a rapid pace inundating medical facilities and creating substantial challenges globally. The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cancer seems to be higher, espe- cially as they are more likely to present with an immuno- compromised condition, either from cancer itself or from the treatments they receive. A major consideration in the delivery of cancer care during the pandemic is to balance the risk of patient exposure and infection with the need to provide effective cancer treatment. Many aspects of the SARS-CoV-2 infection currently remain poorly characterized and even less is known about the course of infection in the context of a patient with cancer. As SARS-CoV-2 is highly contagious, the risk of infection directly affects the cancer patient being treated, other cancer patients in close prox- imity, and health care providers. Infection at any level for patients or providers can cause considerable disruption to even the most effective treatment plans. Lung cancer pa- tients, especially those with reduced lung function and cardiopulmonary comorbidities are more likely to have increased risk and mortality from coronavirus disease 2019 as one of its common manifestations is as an acute respi- ratory illness. The purpose of this manuscript is to present a practical multidisciplinary and international overview to assist in treatment for lung cancer patients during this pandemic, with the caveat that evidence is lacking in many areas. It is expected that firmer recommendations can be developed as more evidence becomes available. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)1119-1136
Number of pages18
JournalJournal of Thoracic Oncology
Issue number7
Publication statusPublished - Jul 2020


  • CELL
  • COVID-19
  • Lung cancer
  • Patient care
  • SARS-CoV-2


Dive into the research topics of 'Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic'. Together they form a unique fingerprint.

Cite this